Robeco Institutional Asset Management B.V. Cuts Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Robeco Institutional Asset Management B.V. cut its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 115,147 shares of the medical research company's stock after selling 3,247 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.06% of IQVIA worth $22,628,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of IQV. R Squared Ltd acquired a new stake in IQVIA in the 4th quarter worth about $360,000. Patriot Financial Group Insurance Agency LLC grew its position in IQVIA by 9.8% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 7,383 shares of the medical research company's stock valued at $1,451,000 after acquiring an additional 661 shares during the period. Perigon Wealth Management LLC increased its stake in IQVIA by 4.9% during the fourth quarter. Perigon Wealth Management LLC now owns 3,007 shares of the medical research company's stock worth $594,000 after acquiring an additional 141 shares during the last quarter. Pacer Advisors Inc. lifted its stake in shares of IQVIA by 1.0% in the 4th quarter. Pacer Advisors Inc. now owns 16,972 shares of the medical research company's stock valued at $3,335,000 after purchasing an additional 172 shares in the last quarter. Finally, KBC Group NV grew its stake in IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company's stock worth $121,109,000 after buying an additional 250,458 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

IQV stock traded down $1.21 during mid-day trading on Monday, reaching $200.15. 862,714 shares of the company traded hands, compared to its average volume of 1,360,378. The company has a market capitalization of $36.33 billion, a P/E ratio of 26.30, a P/E/G ratio of 2.15 and a beta of 1.48. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a fifty day moving average price of $200.41 and a 200-day moving average price of $220.32. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IQV. Leerink Partners reaffirmed an "outperform" rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Robert W. Baird dropped their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Barclays reduced their target price on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a report on Monday. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a report on Monday. Finally, StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $254.53.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.